SOTIO Biotech has presented preclinical data on two of its leading antibody-drug conjugate (ADC) candidates, SOT109 and SOT106, demonstrating strong anti-tumour activity and favourable tolerability profiles across multiple tumour models. 

The data shared at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL supports the candidates’ potential as ADC therapies for various solid tumour types 

SOT109 is tailored to be a best-in-class ADC exploiting the highly promising target of CDH17 for treatment of gastrointestinal cancers including colorectal cancer (CRC).  

ADCs have shown limited clinical success in CRC to date largely due to a lack of ideal target antigens.  

CDH17 is a highly promising target antigen homogenously overexpressed in more than 90% of CRC and abundantly expressed in other GI cancers. Its expression in normal adult tissues is largely restricted to the GI tract, reducing the risk of off-target toxicity.  

SOT109 utilises a proprietary, highly internalising and fully human antibody combined with Synaffix BV’s leading ADC technology platform. 

According to the results, SOT109 exhibited potent efficacy, producing significant and sustained tumour regressions in several in vivo colorectal tumour models, including cell-derived and patient-derived xenografts. 

SOT106 leverages LigaChem Biosciences’ clinically validated ConjuAll ADC platform for tumour-specific MMAE release. 

SOT106 demonstrated exceptional efficacy in an LRRC15 low-expressing patient-derived xenograft model of paediatric osteosarcoma, achieving significant tumour regression where a first-generation LRRC15-targeting ADC benchmark therapy was ineffective. 

“The data we presented at AACR this week highlights the strength of our next-generation ADCs by addressing areas of high unmet need in oncology,” said Martin Steegmaier, Chief Scientific Officer at SOTIO. “SOT109 continues to show excellent tolerability and strong anti-tumour activity across multiple preclinical models of colorectal cancer, while SOT106 offers a novel precision approach with broad applicability in LRRC15+ sarcomas and other solid tumours.”

DIANA SPENCER, Senior Digital Content Editor, DDW